GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » Capital Expenditure

Alar Pharmaceuticals (ROCO:6785) Capital Expenditure : NT$-2.78 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Alar Pharmaceuticals Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Alar Pharmaceuticals's cash flow for capital expenditures for the three months ended in Sep. 2024 was NT$-1.0 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was NT$-2.78 Mil.

Alar Pharmaceuticals Capital Expenditure Historical Data

The historical data trend for Alar Pharmaceuticals's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alar Pharmaceuticals Capital Expenditure Chart

Alar Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial - -0.39 -1.58 -1.14 -6.34

Alar Pharmaceuticals Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1.01 -0.73 -1.04

Alar Pharmaceuticals Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alar Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » Capital Expenditure
Comparable Companies
TPE:1720 ROCO:6576 TPE:4746 TPE:3705 TPE:4119 ROCO:6932 ROCO:4114 TPE:1701 ROCO:4132 TPE:4108 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No. 19, Keyuan Road, Rm. 312, 3rd Floor, Xitun District, Taichung, TWN, 407
Website
https://www.alarpharm.com
Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.

Alar Pharmaceuticals Headlines

No Headlines